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Neurosteroids are steroids made by brain cells independently of peripheral steroidogenic
sources. The biosynthesis of most neurosteroids is mediated by proteins and enzymes
similar to those identiﬁed in the steroidogenic pathway of adrenal and gonadal cells. Dehy-
droepiandrosterone (DHEA) is a major neurosteroid identiﬁed in the brain. Over the years
we have reported that, unlike other neurosteroids, DHEA biosynthesis in rat, bovine, and
human brain is mediated by an oxidative stress-mediated mechanism, independent of
the cytochrome P450 17α-hydroxylase/17,20-lyase (CYP17A1) enzyme activity found in the
periphery. This alternative pathway is induced by pro-oxidant agents, such as Fe2+ and
β-amyloid peptide. Neurosteroids are involved in many aspects of brain function, and as
such, are involved in various neuropathologies, including Alzheimer’s disease (AD). AD is a
progressive, yet irreversible neurodegenerative disease for which there are limited means
for ante-mortem diagnosis. Using brain tissue specimens from control and AD patients, we
provided evidence that DHEA is formed in the AD brain by the oxidative stress-mediated
metabolism of an unidentiﬁed precursor, thus depleting levels of the precursor in the blood
stream.We tested for the presence of this DHEA precursor in human serum using a Fe2+-
based reaction and determined the amounts of DHEA formed. Fe2+ treatment of the serum
resulted in a dramatic increase in DHEA levels in control patients, whereas only a moderate
or no increase was observed in AD patients. The DHEA variation after oxidation correlated
with the patients’ cognitive and mental status. In this review, we present the cumulative
evidence for oxidative stress as a natural regulator of DHEA formation and the use of this
concept to develop a blood-based diagnostic tool for neurodegenerative diseases linked to
oxidative stress, such as AD.
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INTRODUCTION
The crucial roles of steroid hormones in the development and
function of the central nervous system (CNS) have been well
established (Compagnone and Mellon, 1998; Baulieu et al., 1999;
Karishma and Herbert, 2002; Suzuki et al., 2004; Wang et al.,
2005). Depending on their chemical structure and plasma con-
centrations, steroids can exert either protective or adverse effects
on neural tissues (Kimonides et al., 1998; Schumacher et al.,
2000; Wise et al., 2001; Charalampopoulos et al., 2004, 2006; Mel-
cangi and Panzica, 2006; Singh, 2006). Whereas many steroids
originate from peripheral steroidogenic organs, such as adren-
als and gonads, recent research has shown that some steroids are
synthesized in the nervous system and display beneﬁcial neu-
roprotective properties, which may be of particular importance
in treating diseases in which neurodegeneration is predominant,
including age-dependent dementia, stroke, epilepsy, spinal cord
injury, Alzheimer’s disease (AD), Parkinson’s disease (PD), and
Niemann–Pick type C disease (NP-C). Neurosteroids, according
to the deﬁnition proposed by Baulieu (1997), are steroid hor-
mones that are synthesized in the central and peripheral nervous
systems, either de novo from cholesterol or by in situ metabolismof
blood-borne precursors, and that accumulate in the nervous sys-
tem independently of the classical steroidogenic gland secretion
rates. The term “neuroactive steroids” refers to steroid hormones
that exert their effects on neural tissue. Neuroactive steroids may
be synthesized in both the nervous systemand in endocrine glands.
Neurosteroids exert a wide array of biological activities in the
brain (Lapchak and Araujo, 2001; Belelli et al., 2006; Strous et al.,
2006), either through conventional genomic action or interaction
with membrane receptors. In particular, neurosteroids have been
found to act as allosteric modulators of the GABAA/central type
benzodiazepine receptor complex (Majewska, 1992; Covey et al.,
2001; Lapchak andAraujo, 2001),N -methyl d-aspartate (NMDA)
receptors (Jang et al., 2004; Mameli et al., 2005), kainate recep-
tors (Costa et al., 2000; Dubrovsky, 2005), α-amino-3-hydroxy-
5-methyl-4-isoxazolepropionic acid AMPA receptors (Rupprecht
and Holsboer, 2001; Rupprecht et al., 2001), sigma receptors
(Monnet et al., 1995; Maurice et al., 1996, 1999, 2006; Takebayashi
et al., 2004), glycine receptors (Maksay et al., 2001; Jiang et al.,
2006; Mitchell et al., 2007), serotonin receptors (Kostowski and
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Bienkowski, 1999; Shannon et al., 2005), nicotinic receptors (Par-
adiso et al., 2000; Pereira et al., 2002; Arias et al., 2006), and
muscarinic receptors (Horishita et al., 2005; Steffensen et al., 2006).
More recently, it was reported that neurosteroids may directly acti-
vateG-protein-coupledmembrane receptors (Ueda et al., 2001;He
et al., 2003; Zhu et al., 2003; Schiess and Partridge, 2005; Tasker,
2006) or indirectly modulate binding of neuropeptides to their
receptors (Sullivan and Moenter, 2003; Torres and Ortega, 2003;
Lipschitz et al., 2005). Finally, neurosteroids have been shown to
bind to microtubule-associated protein 2 (MAP2) and to stim-
ulate tubulin polymerization in cultured neurons. In fact, the
binding of dehydroepiandrosterone (DHEA) and pregnenolone
(PREG) to MAP2 involved polar and hydrophobic interactions,
such the hydrogen bonds, and was localized at the N-terminal
domain of the protein. This domain is speciﬁc to high molecu-
lar weight MAP2 isoforms, and absent in other MAPs, notably
Tau, a component of AD pathology. In AD and other tauopathies
the Tau protein forms ﬁbrillar deposits in the brain. The difference
between the N-terminal sequence of MAP2 and Tau could account
for the difference in their aggregation properties. The direct inter-
action of DHEA and PREG with MAP2 raises the possibility that,
in addition to the well-known steroid hormone–receptor inter-
actions, direct interaction of neurosteroids with the cytoskeleton
may participate in brain plasticity (Murakami et al., 2000; Laurine
et al., 2003; Iwata et al., 2005).
In vivo studies also indicate that neurosteroids are involved in
regulating various neurophysiological and behavioral processes,
including cognition, stress, depression, anxiety, and sleep, as well
as in sexual- and feeding-related behaviors and locomotion (Vallee
et al., 1997, 2001; Engel and Grant, 2001; Mayo et al., 2003;
Schumacher et al., 2004; Dubrovsky, 2005, 2006; Mellon, 2007;
Mitchell et al., 2008). Paradoxically, although steroids play major
roles as signaling molecules within the brain, to date, little is
known regarding the neural mechanisms regulating neurosteroid
biosynthesis in the CNS.
In this review, we present evidence for oxidative stress as a nat-
ural regulator of speciﬁc neurosteroid formation. This alternative
steroid biosynthesis pathway was used to develop a blood-based
diagnostic tool for neurodegenerative diseases linked to oxida-
tive stress, like AD, with the goal of monitoring the onset and
progression of the disease as well as its response to existing and
experimental therapies.
PATHWAYS OF NEUROSTEROID BIOSYNTHESIS
It has long been thought that steroidogenic glands, including the
adrenal cortex, gonads, and placenta, were the only sources of
steroids that could act on the brain.However, seminal observations
made by the Baulieu and Robel group have shown that this view is
incorrect. First, these authors discovered that the concentrations of
several steroids, such as PREG, DHEA, and their sulfate esters are
much higher in the brain than in the plasma (Baulieu, 1981; Cor-
pechot et al., 1981, 1983). Second, they showed that the levels of
these steroids in brain tissue remain elevated long after adrenalec-
tomy and castration (Cheney et al., 1995). Third, they found that
the circadian variations of steroid concentrations in brain tissue
are not synchronizedwith those of circulating steroids (Robel et al.,
1986). These observations led them to propose that the brain can
actually synthesize biologically active steroids, or “neurosteroids”
(Robel and Baulieu, 1985, 1994; Baulieu, 1997, 1998).
Steroid biosynthesis begins with the transfer of free cholesterol
from intracellular stores into mitochondria. Two proteins appear
to play a crucial role in intramitochondrial cholesterol trans-
port: the peripheral-type benzodiazepine receptor (Papadopoulos,
1993), renamed translocator protein 18 kDa (TSPO; Papadopou-
los et al., 2006; Rone et al., 2009), and the steroidogenic acute
regulatory protein (STAR; Stocco and Clark, 1996). TSPO serves
as a gatekeeper in protein and cholesterol import into mitochon-
dria, and STAR serves the role of the hormone-induced activator.
Thus, both proteins work in concert to bring cholesterol into
mitochondria (Hauet et al., 2005).
The ﬁrst step in the biosynthesis of neurosteroids is the
conversion of cholesterol to PREG. This reaction is cat-
alyzed by the cytochrome P450 cholesterol side-chain cleav-
age (P450scc; CYP11A1) in three successive chemical reactions:
20α-hydroxylation, 22-hydroxylation, and scission of the C20–
C22 carbon bond of cholesterol. The products of this reac-
tion are PREG and isocaproic acid. PREG can be converted to
DHEA via cytochrome P450c17 (CYP17A1). Both PREG and
DHEA are 3β-hydroxy-Δ5-steroids, which are present in neural
tissue in the free forms and their sulfate ester forms. 17β-
hydroxysteroid dehydrogenase (17β-HSD) and 3β-hydroxysteroid
dehydrogenase-isomerase (3β-HSD) mediate the conversion of
DHEA into androgens. The cytochrome P450 aromatase (CYP19)
converts testosterone to estradiol, whereas 5α-reductase converts
testosterone to dihydrotestosterone. PREG can be oxidized to
active 3-oxo-Δ4-steroids, such as progesterone (PROG), by 3β-
HSD. PROG is a substrate for 5α/β-reductase enzymes and is
converted into 5α/β-dihydroprogesterone (5α/β-DH PROG). Fur-
ther reduction of 5α/β-DH PROG at the C3 position, by the 3α-
hydroxysteroid oxidoreductase (3α-HSOR), yields 3α-hydroxy-
5α/β-pregnan-20-one (3α,5α/β-tetrahydroprogesterone; 3α,5α/β-
TH PROG; allopregnanolone; Mellon et al., 2001; Plassart-Schiess
and Baulieu, 2001).
NEUROSTEROID ACTION IN NEUROBEHAVIORAL DISORDERS
Considering the role identiﬁed for TSPO in steroid biosynthesis
in peripheral tissues, Papadopoulos et al. (1992, 2006) investi-
gated whether TSPO ligands affect PREG formation in glioma cell
mitochondria. We showed that at nanomolar levels, high-afﬁnity
TSPO drug ligands increase PREG production (Papadopoulos
et al., 1992, 2006; Rupprecht et al., 2010). These results were
conﬁrmed in situ in rat and human glioma cell cultures upon
addition of the precursor mevalonactone (Guarneri et al., 1992;
Brown et al., 2000). In addition, TSPO drug ligands were found
to increase allopregnanolone levels in vivo in rat forebrain (Kor-
neyev et al., 1993; Costa et al., 1994; Trapani et al., 2005) and
hippocampus (Bitran et al., 2000), and to induce antineopho-
bic, anticonﬂict, and anxiolytic actions via their TSPO-mediated
steroidogenic effect and the subsequent action of the synthe-
sized neuroactive steroids on the GABAA receptor (Costa et al.,
1994; Bitran et al., 2000). Thus, if TSPO levels in the CNS are
reduced, neurosteroid synthesis also will be reduced. This decrease
will act at the beginning of the pathway, controlling the supply
of cholesterol to support neurosteroid biosynthesis that may be
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reduced under various pathological conditions, such as anxiety
disorders.
To determine the function of increased TSPO levels in AD, the
Papadopoulos lab investigated the levels of steroids present in var-
ious brain areas in specimens obtained from postmortem AD and
age-matched controls, with a focus on DHEA (Brown et al., 2003).
DHEA PROPERTIES
DHEA and its sulfate ester dehydroepiandrosterone sulfate
(DHEA-S) were identiﬁed in the brain by Baulieu et al. (1965).
DHEA is a major neuroactive steroid that exerts a broad range
of biological effects and constitutes the majority of neurosteroids
found in the brain (Baulieu and Robel, 1996). Various studies
showed that DHEA also has functions on modulating mem-
brane receptors, such as NMDA, GABA, sigma receptors, and on
Ca2+ channels (Compagnone and Mellon, 1998). These effects
may explain, at least in part, its ability to protect hippocampal
(Kimonides et al., 1998) and brain cells (Roberts et al., 1987),
to regulate neuronal activity (Meyer and Gruol, 1994), and to
enhance or restore memory and learning processes (Maurice et al.,
1998). Finally, the sulfate esterDHEA-Shas been shown to enhance
the in vitro release of hippocampal acetylcholine (Rhodes et al.,
1997), a neurotransmitter likely involved in memory processes
and impairment in AD (Kasa et al., 1997). It is well-known that
DHEA also displays antioxidant properties, because it can reduce
lipid peroxidation in the rat brain (Aragno et al., 1997; Boccuzzi
et al., 1997) and in the periphery in older humans (Araghiniknam
et al., 1996).
DHEA peripheral levels peak early in adulthood and gradually
decline with age (Baulieu, 1996; Parker, 1999). The role of DHEA
in the periphery is not well established, but DHEA may serve as a
precursor for androgens and estrogens. The levels of DHEA in the
brain were found to exceed those seen in the periphery, and these
levels were maintained after removal of the peripheral steroido-
genic endocrine glands (Corpechot et al., 1981; Akwa et al., 1991).
The neurotrophic effects of DHEA were ﬁrst reported in mouse
brain cell cultures (Roberts et al., 1987) and DHEA was subse-
quently found to protect rat and human hippocampal neuronal
cells against oxidative stress-induced cellular damage (Bastianetto
et al., 1999).Givenneuroprotective and cognitive-enhancingprop-
erties of DHEA, it has beenhypothesized that elevatedDHEA levels
observed in AD brain tissue potentially represent an adaptive or
compensatory process (Alhaj et al., 2006).
CYP17A1-INDEPENDENT PATHWAY FOR DHEA FORMATION
Baulieu and Robel (1990) demonstrated that PREG and DHEA
accumulate in the brain independently of the supply by peripheral
endocrine organs (Baulieu and Robel, 1990). Despite these initial
ﬁndings and numerous subsequent studies, the data available to
date on the synthesis of DHEA do not account for the mecha-
nisms responsible for its synthesis. First, the levels of CYP17A1
enzymatic activity, immunoreactivity, and mRNA are not con-
sistent with each other (Mellon and Deschepper, 1993). Second,
neither CYP17A1 protein nor its activity has been detected in the
brain (Le Goascogne et al., 1995). Only transient expression of the
mRNA for this enzyme during embryonic life was reported (Com-
pagnone et al., 1995) and contradictory data on the presence of its
mRNA in the adult have been presented (Sanne andKrueger, 1995;
Stromstedt and Waterman, 1995). Thus, the pathway by which
DHEA is synthesized in the adult brain is unknown, and brain
steroid synthesis seemingly may not ﬁt in at all with the steps of
the well-accepted scheme for adrenal and gonadal steroidogene-
sis, suggesting that alternate pathways for the synthesis of some
steroids, such as DHEA, may exist.
Prasad et al. (1994) proposed the existence of a few alterna-
tive precursors present in rat brain extracts that can react with
compounds unrelated to peripheral steroid biosynthesis and pro-
duce neurosteroids. These authors demonstrated that treatment
of organic extracts of rat brain with different oxidizing and reduc-
ing compounds not known to cleave lipoidal or sulfate conjugates
resulted in the liberation of DHEA. The results were based on
experiments that compared the concentrations of these steroids
found in the treated aliquots with those measured in untreated
samples estimated by mass spectrometric analysis. Cascio et al.
(1998) subsequently reported that rat tumor glioma cells, which
do not contain the enzyme CYP17A1, are still able to produce
DHEA through an alternative pathway. The same pathway was
also found inMA-10 Leydig tumor cells.However, in Leydig tumor
cells, this process accounts for only a small portion of the steroids
produced, suggesting that in this steroidogenic tissue, the princi-
pal pathway by which DHEA is biosynthesized involves CYP17A1.
Because CYP17A1 enzyme, protein, and activity have not yet been
found in rat and guinea pig brain (Mellon and Deschepper, 1993;
Baulieu, 1996) where high levels of DHEA have been measured, it
may be possible that this DHEA arises from a similar alternative
process.
OTHER ALTERNATIVE PATHWAYS FOR STEROID
BIOSYNTHESIS
Several studies have shown that steroids may be formed via
alternative biosynthesis pathways. Some pathways are described
as microbial aerobic pathways, and many steroidal components
have been detected in axillary secretions, such as the unsaturated
steroids of the androstane (C19) family, where the precursors
and the biochemical routes of production remain matters for
debate (Austin and Ellis, 2003). Other studies have proposed the
existence of a “sodium status factor” that regulates aldosterone
biosynthesis whereby during severe sodium deﬁciency, there is a
switch in the aldosterone pathway to a pathway using 18-hydroxy-
deoxycorticosterone rather than corticosterone as an intermediate
(Boon et al., 1998). Moreover, some studies have shown that
biotransformation of lithocholic acid by Pseudomonas sp. strain
NCIB 10590 under anaerobic conditions leads to a wide range
of steroidal products, such as androsta-1,4-diene-3,17-dione 17β-
hydroxyandrost-4-ene-3-one, 17β-hydroxyandrosta-1,4-diene-3-
one, 3-oxo-5β-cholan-24-oic acid, 3-oxochola-1,4-diene-24-oic
acid, 3-oxopregn-4-ene-20-carboxylic acid, and 3-oxopregna-1,4-
diene-20 carboxylic acid (Owen and Bilton, 1984).
OXIDATIVE STRESS, β-AMYLOID (Aβ) PEPTIDE, IRON, AND
DHEA LEVELS
The generation of oxygen radicals has been implicated in all types
of neurodegenerative diseases (Coyle and Puttfarcken, 1993). Evi-
dence of increased oxidative stress has been shown in the AD
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brain (Subbarao et al., 1990; Mecocci et al., 1994; Smith et al.,
1995), where it contributes to the formation of amyloid plaques
and neuroﬁbrillary tangles (Dyrks et al., 1992; Smith et al., 1994).
A possible source of oxidative stress in the AD brain is the Aβ
peptide. Aβ is a component of AD plaques (Joachim and Selkoe,
1992) and can cause increases in reactive oxygen species (ROS)
via several mechanisms. Aβ can acquire a free radical state on its
own (Hensley et al., 1994) or activate microglia to produce free
radicals (Klegeris et al., 1994; Klegeris and McGeer, 1997). Studies
have shown that addition of Aβ to PC12 cells results in increased
intracellular calcium levels and oxygen radical production, lead-
ing to mitochondrial dysfunction and apoptosis (Guo et al.,
1998). These events can be prevented using antioxidants such as
vitamin E (Guo et al., 1996).
These ﬁndings led us to hypothesize that if the alternative path-
way of DHEA formation is present in human brain tissue, DHEA
formation should be elevated in AD brain tissue due to the pres-
ence of increasedAβ and oxidative stress levels. Brown et al. (2003)
measured the levels of DHEA in AD and age-matched control
brains and indeed found that DHEA levels are signiﬁcantly higher
in theADbrain in all three areas examined, and aremaximal inAD
hippocampus. Thismay reﬂect increased oxidative stress in theAD
brain, potentially due to the actions of Aβ. Aβ, a major component
of AD neuritic plaques (Joachim and Selkoe, 1992), increases free
radicals in neurons (Subbarao et al., 1990; Mecocci et al., 1994;
Nunomura et al., 2000) and glia (Brown et al., 2000), and directly
produces hydrogen peroxide through metal ion reduction (Huang
et al., 1999). Other studies have shown increased levels of car-
bonyls in neuronal cytoplasm and in nuclei of neurons and glia
from AD brains (Smith et al., 1995), as well as increases in lipid
peroxidation, protein peroxidation, disruption of mitochondria
energy metabolism in AD, and increased RNA oxidation, suggest-
ing a role for ROS in the development of AD (Subbarao et al.,
1990; Mecocci et al., 1994; Markesbery, 1997; Nunomura et al.,
2000). Indeed, it is now well established that Aβ and oxidative
stress play major roles in the pathogenesis of AD (Markesbery,
1997).
In addition to AD pathology, head trauma and stroke-related
massive bleeding may also signiﬁcantly produce iron-mediated
oxidative stress and neurodegeneration. In AD, iron accumulation
in AD plaques and neuroﬁbrillary tangles can act as a source of
redox-generated free radicals (Smith et al., 1997). If our hypoth-
esis is correct, we expect DHEA levels to be elevated in patients
with AD, a disease that involves increased iron and oxidative stress
levels. Indeed, as stated above, Brown et al. (2003) reported that
DHEA levels are signiﬁcantly higher in all regions of the AD brain
compared to age-matched control brain (Brown et al., 2003). Fur-
thermore, increased oxidative stress-induced by either positive
ions (ferrous, copper, zinc, etc.) or Aβwas shown to induce DHEA
formation by human brain cells in vitro (Brown et al., 2000).
Fe2+ TRIGGERS THE ALTERNATIVE PATHWAY
As noted above, iron (Fe) is a signiﬁcant component of senile
plaques, and iron inlays of blood vessels are common in AD. Fe2+
levels are elevated and ironmobility decreased inADbrains (Beard
et al., 1993). Fe2+ used to trigger the alternative pathway causes
an increase in ROS, both by the formation of ferric iron and
superoxide and by reacting with hydrogen peroxide to form the
hydroxyl radical by Fenton reaction (Figure 1; Galey, 1997). Con-
sidering the effect of Fe2+ on ROS and DHEA formation, Cascio
et al. (2000) showed that Aβ causes an increase in oxygen free
radicals in cells, and this rise in free radicals affects DHEA levels
(Cascio et al., 2000).
The structure of at least one form of a putative DHEA precur-
sor of the CYP17A1-independent pathway was suggested by the
results obtained with Fe2+ (Prasad et al., 1994). This ion, consid-
ered as a reducing agent, is known to produce carbonyl-containing
compounds from hydroperoxides (Hawkins, 1949; Hawkins and
Young, 1950). This reaction occurs by one-electron reduction of
the O-O bond of the peroxide, with subsequent fragmentation of
the resulting alkoxy radical (Figure 2). Therefore, the lability of
such molecules to heat, air, light, and other environmental con-
ditions may make a delusive contribution to the concentrations
of the free neurosteroids estimated by other analytical methods
(Mathur et al., 1993). Hawkins and Young (1950) have shown,
treatment of tertiary hydroperoxides with aqueous solutions of
FeSO4 leads to several products, only one of which may be a
ketone.
Fe2+ ions affect many cellular processes, including those that
stimulate oxygenases and hydroxylases. It is also conceivable that
Fe2+ forms complexes with constituents within glioma cells that
are able tomimic the catalytic oxidative behavior of a P450 enzyme
(Brown et al., 2003). It should be noted that although Fe2+ is a
pleiotropic agent in the CNS, the speciﬁcity of its reaction with
endogenous precursors to form DHEA is characterized by the fol-
lowing observations: (i) it is speciﬁc for the formation of DHEA
because no effect on PROG production is seen; (ii) it appears to be
FIGURE 1 | Fenton’s reaction occurs between hydrogen peroxide and
Ferrous Iron(II). Ferrous Iron(II) oxidized by hydrogen peroxide to ferric
iron(III), a hydroxyl radical, and a hydroxyl anion. Iron(III) is then reduced back
to iron(II), a peroxide radical, and a proton by the same hydrogen peroxide.
FIGURE 2 | Mechanism of ketone formation from hydroperoxides.This
scheme illustrates how the addition of FeSO4 could reduce the
17-hydroperoxide of PREG to an intermediate alkoxy radical. Cleavage of the
two-carbon side-chain by b-fragmentation results in the formation of DHEA.
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tissue-speciﬁc; (iii) its action is found in the microsomal fraction;
(iv) it is dose dependent, but not in a stoichiometric manner; and
(v) the effect of FeSO4 could not be replicated to the same extent
when using FeCl3 or H2O2.
NATURE OF THE DHEA PRECURSORS
The suggestion that an alternate pathway involving a hydroperox-
ide could exist for the biosynthesis of steroid hormones was ﬁrst
proposed by Van Lier and Smith (1970). They showed that the 20-
hydroperoxide derivative of cholesterol could be converted into
PREG by incubation with adrenal cortex mitochondrial enzymes.
Thus, a pathway involving sterol peroxide as the precursor of PREG
or DHEA could differ from the traditional one.
Cascio et al. (1998) reported that addition of FeSO4 directly to
glial cells in culture resulted in a 5- to 10-fold increase in DHEA.
This is probably due to the fragmentation of an in situ-formed
tertiary hydroperoxide initiated by Fe2+. Evidence already exists
that mammalian tissues contain enzymes that catalyze the frag-
mentation of peroxy constituents to steroid ketones. Larroque
and Van Lier (1986) found that when 20-hydroperoxycholesterol
is incubated with puriﬁed P450scc for only 30 s at 0˚C, it is
readily converted to PREG. Moreover, Tan and Rousseau (1975)
showed that in the rat testis, microsomal fraction can convert 17-
hydroperoxyprogesterone to androstenedione when incubated in
the presence of oxygen and nicotinamide adenine dinucleotide
phosphate. The cofactor was essential, but oxygenwas not, because
they showed that oxygen can be substituted with argon. These
authors also reported that the 17-hydroperoxide can be trapped
when PROG is incubated with adrenal homogenates in the pres-
ence of the hydroxylase inhibitor p-hydroxymercuribenzoate (Tan
and Rousseau, 1975). Adding exogenous PREG along with FeSO4
to C6 microsomes results in a large increase in the amount
of DHEA formed. This example, perhaps the ﬁrst, of a mam-
malian brain cell converting PREG to DHEA indicates that Fe2+
can activate the conversion process, which may, in fact, involve
hydroperoxylation at C17 of the added PREG.
Further studies showed that the peroxy-precursor of DHEA is
not soluble in organic solvents, suggesting the potential require-
ment for a cellular component for activity. Thus, the effect of Fe2+
on the formation of DHEA may be mediated by a protein micro-
somal component associated with iron reduction. However, since
the peroxy-precursor(s) of DHEAmade in C6 cells was not soluble
in organic solvents, it appears that the process for making DHEA
in C6 cells is more complicated than that which simply involves
fragmentation of peroxy compounds (Cascio et al., 1998).
Previous reports (Parton et al., 1994; Sawyer et al., 1994) sug-
gested that the level of activation of oxygen is similar to that for
Fenton reagents and P450 hydroxylases, and thus it can affect oxy-
gen insertion at the C17 bond. Therefore, we cannot be certain
of the mechanism(s) by which Fe2+ acts and increases DHEA
production in C6 glioma cells. However, the absence of CYP17A1
activity, protein, andmRNA in these glial cells indicates that,what-
ever process leads to DHEA formation in these cells, it differs from
that involving this steroidogenic enzyme. Even if Fe2+ stimulates
an existing enzyme to produceDHEA, the precursor of thatDHEA
also appears to differ from the precursor customarily assumed to
be used in peripheral steroidogenic tissues.
Indeed, addition of exogenous PREG is an artiﬁcial way to
demonstrate the physiological role and activity of CYP17A1.
Therefore, it is important to perform experiments on alternative
pathways of steroid synthesis in the absence of the precursor to
identify alternative activities. Cascio et al. (2000) proposed that
the ﬁnal answer to the question of how DHEA is made in the
brain will depend on the isolation and characterization of brain
CYP17A1 or the Fe2+-dependent activity (Cascio et al., 2000).
However, in the human brain, all cell types (neurons, oligoden-
drocytes, and astrocytes) express message and protein CYP17A1,
but show no CYP17A1 activity. Nevertheless and as mentioned
before, addition of Fe2+ or Aβ increases cellular ROS and results
in the formation of DHEA (Brown et al., 2000).
Brown et al. (2000) showed a ROS-induced DHEA synthesis,
which may vary between oligodendrocytes and astrocytes. Astro-
cytes seem to produce more ROS in response to Fe2+ than glioma
cells, which may indicate an increased sensitivity to FeSO4 and
potentially a higher activity for ROS regulation of DHEA syn-
thesis in normal human brain cells. These data suggest that the
oxidative environment of the brain under different conditionsmay
inﬂuence DHEA formation by glia. Neurons do not have the alter-
native pathway for DHEA synthesis, suggesting that the alternative
pathway is speciﬁc to glia. Oligodendrocytes that do not respond
to Fe2+ can synthesize DHEA de novo in a CYP17A1-independent
manner, potentially due to high endogenous levels of ROS (Brown
et al., 2000).
In support of these ﬁndings, the CYP17A1 inhibitor SU10603
(LaCagnin et al., 1989) was found to not affect PREG levels in
any of the cell lines used, indicating that this drug is not alter-
ing CYP11A1 activity or PREG metabolism. Considering that
SU10603 did not inhibit DHEA formation in any human brain
cell system tested, a conclusion could be made that CYP17A1 does
not mediate DHEA formation in human brain cells.
AD AND A CYP17A1-INDEPENDENT PATHWAY
Brown et al. (2003) examined the potential for alternative path-
way activity in AD and age-matched control brain specimens
(Figure 3). Treatment with the reducing reagent FeSO4 caused
a signiﬁcant increase in DHEA levels in the hippocampus and
cortex of control patients, possibly indicating the presence of an
alternative precursor in these areas. AD patients showed a signiﬁ-
cant increase in DHEA levels only in the frontal cortex, indicating
the presence of an alternative precursor is in this area, but not in
theADhypothalamusor hippocampus. Thehigher levels of DHEA
present in the hypothalamus and hippocampus of the AD brain
before FeSO4 treatment suggest that the precursor of the alterna-
tive pathway has already been converted to DHEA by endogenous
oxidative stress due to the disease process (Brown et al., 2003).
The role of the neurosteroid DHEA in aging is unknown,
although a number of attempts have been made to link low serum
DHEA with dementia and memory disorders, particularly AD
(Berr et al., 1996; Guazzo et al., 1996; Baulieu, 1997; Wolf et al.,
1997a,b). Although DHEA levels are lower inAD serum compared
to controls, the differences seen may not be as signiﬁcant due to
high variability among specimens (Lacroix et al., 1987; Rammouz
et al., 2011). Thus, although DHEA is known to affect NMDA
receptors (Bergeron et al., 1996) and to potentiate both memory
www.frontiersin.org November 2011 | Volume 2 | Article 69 | 5
Rammouz et al. Brain DHEA formation and Alzheimer’s disease
FIGURE 3 | Samples were extracted, and DHEA was purified by HPLC
and measured using a specific radioimmunoassay. DHEA levels (pg/mg
protein) in brain samples from AD and age-matched control patients with
and without treatment with 30mM FeSO4 (adapted from Brown et al.,
2003).
formation (Flood et al., 1992) and hippocampal long-term poten-
tiation (Yoo et al., 1996), there is no in vivo evidence for its role in
memory and dementia.
Liu et al. (2009) reported the ﬁrst in vivo evidence for the
existence of DHEA in brain tissue coming from a CYP17A1-
independent pathway present in peripheral steroidogenic tissues
using a CYP17A1 chimeric mouse model. In CYP17A1 chimeric
mice, the Leydig cell CYP17A1 mRNA and intratesticular and
circulating testosterone levels were reduced by 65%, which is in
agreement with previous data and consistent with the role of
CYP17A1 in peripheral steroidogenesis (Liu et al., 2009). In the
same study, the authors observed that although the CYP17A1 pro-
tein was undetectable in adult mouse brain extracts, CYP17A1
mRNAwas present, but was reduced by 50% inCYP17A1 chimeric
mouse brain compared to wild-type brain tissue. Despite this dif-
ference in CYP17A1 mRNA levels and lack of CYP17A1 protein,
CYP17A1 chimeric mice contained the same endogenous levels
of DHEA as wild-type mice. These data raised the question of
whether CYP17A1 activity is required for the synthesis of DHEA
in adult mouse brain tissue. In support of these ﬁndings, Maayan
et al. (2005) reported that the increased DHEA synthesis seen
in the brain of castrated male mice was completely blocked by
the antioxidant N -acetylcysteine amide. The CYP17A1 and 3β-
HSD inhibitors SU10693 and trilostane, respectively, did not block
the FeSO4-induced DHEA formation, providing additional evi-
dence that CYP17A1 does not mediate the Fe2+-induced DHEA
synthesis in the adult mouse brain.
A reduction of DHEA levels throughout development would
be expected to affect the cognitive process of the CYP17A1
chimeric mice. However, no spatial memory deﬁciency was seen
in the CYP17A1 chimeric mice in comparison to wild-type mice,
suggesting that CYP17A1 gene deletion and the reduction of
CYP17A1 mRNA levels in the brain did not affect learning or
memory. This ﬁnding is supported by clinical studies frompatients
with CYP17A1 defects (Yanase, 1995). Indeed, there are no reports
of cognitive deﬁciencies in CYP17A1-deﬁcient patients. These
results demonstrate the lack of relationship between learning and
memory and CYP17A1 expression in brain. Considering the pro-
posed roles of DHEA in neuronal function, DHEA production
defects in humans would be expected to have a dramatic impact
on brain development and function. The only explanation for
the lack of cognitive deﬁcits in CYP17A1-deﬁcient patients and
the chimeric mouse model is that DHEA is synthesized by a
CYP17A1-independent, Fe2+-sensitive pathway that maintains or
compensates for reduced DHEA synthesis.
In further support of a CYP11A1-independent pathway in AD,
Brown et al. (2003) measured CYP17A1, and whereas CYP17A1
mRNA was found in the frontal cortex of control and AD patients,
there was no CYP17A1 mRNA or immunoreactivity was detected
in the hippocampus (Brown et al., 2003). In contrast, the enzyme
CYP11A1 was present in all specimens, suggesting that these tis-
sues can synthesize PREG from cholesterol. Thus, the high levels
of DHEA found in the AD brain are either derived from periph-
eral sources and accumulated and stored in speciﬁc brain regions,
such as the hippocampus, or are derived from local activity of the
alternative pathway.
CYP17A1-INDEPENDENT PATHWAY IN THE DIAGNOSTIC OF
NEURODEGENERATIVE DISEASES
One of the major problems with AD diagnosis and treatment is
the inability to determine the onset of the disease. Currently, AD
diagnosis is performed using a combination of magnetic reso-
nance imaging scans tomeasure generalized shrinkage of the brain,
and cognitive tests to determine the state of dementia. Unfor-
tunately, symptoms typically do not occur until very late in the
disease process. If the changes in DHEA in the cerebral spinal ﬂuid
(CSF) are indeed regulated by oxidative stress conditions within
the brain, alterations in CSF DHEA levels may occur very early in
the progression of the disease. Furthermore, analysis of the data
in Figure 3 (Brown et al., 2000) suggests that the serum shows
a greater response to FeSO4 treatment than does any brain area
tested. Because there was an increase in all control sera after FeSO4
treatment, but no change in AD sera, the serum may be a useful
compartment for determining the progression of brain oxidative
stress in AD. Therefore, by determining whether the alternative
precursor is present in the blood, and measuring CSF DHEA lev-
els, it may be possible to determine the conditions of oxidative
stress in the brain. The availability of the alternate precursor for
DHEA in serum could thus be used as a diagnostic tool to identify
the onset and follow the progression of AD.
It has been long speculated thatDHEA is important in the aging
process, particularly in modulating memory formation (Parker,
1999). Although serum DHEA levels decrease with age in the
human, there are no available studies on the levels of DHEA in the
brain. Several groups have tried to correlate serum levels of DHEA
and DHEA sulfate with cognitive function (Guazzo et al., 1996)
or future development of AD (Berr et al., 1996), but these studies
have failed to ﬁnd a connection between DHEA levels and cogni-
tive ability, or to demonstrate serum DHEA levels as a predictor
of future AD development.
Contrary to current hypotheses, we reported that DHEA lev-
els are much higher in the AD brain than in age-matched control
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specimens (Brown et al., 2003). Additionally, we demonstrated
that: (i) in contrast to decreasing serum levels of DHEA in patients
withAD,brain DHEA is signiﬁcantly higher inAD patients than in
age-matched controls; and (ii) CYP17A1 protein and mRNA are
not found in the hippocampus. In agreement with these observa-
tions, DHEA levels in the brain tissue and the CSF of AD patients
are signiﬁcantly higher than in controls. Furthermore, there is evi-
dence for alternative pathway activity in specimens from both AD
and control patients, although treatment of control, but not AD,
sera with FeSO4 results in increased DHEA levels. Thus, the mea-
surement of CSF DHEA levels, in conjunction with serum DHEA
levels and alternative pathway activity examined in the presence
of FeSO4, could be used as a predictive diagnostic measurement
of AD neuropathology.
Although a larger sampling is required to validate the results
of Brown et al. (2003), we speculated that by measuring DHEA
levels in the serum and CSF of aging patients, and looking for
evidence of alternative pathway activity in these compartments, it
may be possible to determine early changes in the levels of oxida-
tive stress in the brain. These changes could reﬂect early damage in
AD or even in other neurodegenerative disorders involving oxida-
tive stress. We investigated the presence of the DHEA precursor
in human serum using a Fe2+-based reaction and determined the
amounts of DHEA formed in 86 subjects (Rammouz et al., 2011).
Our results conﬁrmed the preliminary data of Brown et al. (2003).
Indeed, in vitro oxidation of sera from aged-matched control sub-
jects led to a more than 50% increase in DHEA levels compared
to respective baseline levels. This increase was signiﬁcantly higher
than that observed in AD patients (14 and 3% increases in the
mild and severe AD groups, respectively) assessed using the mini-
mental state examination (Figure 4). Interestingly, the correlation
between cognitive impairment and percent DHEA increase in the
oxidative pathway seemed to be stronger in women than in men.
However, more samples must be analyzed before we can reach any
conclusions on gender differences in the evolution and outcomes
of AD.
Mild cognitive impairment (MCI) is currently proposed as
a transition state between normal aging and dementia (Mariani
et al., 2007). Although MCI is a rather elusive entity for which no
consensual deﬁnition has been provided, it is commonly divided
into two groups: amnestic MCI, which is thought to be an early
stage of AD, and non-amnestic MCI, which is associated with cog-
nitive alterations other than memory. Because MCI is considered
an early stage of dementia and early diagnosis can lead to clinically
relevant treatment,a diagnostic tool for early stage identiﬁcationof
the disease is required to allow clinicians to discriminateMCI from
AD. This subset of data demonstrates that monitoring oxidative
stress-mediated DHEA formation in sera allows one to discrimi-
nate MCI from healthy subjects, and more so from AD patients,
regardless of the severity of the disease status.
Many candidate disease-modifying therapies that target the
underlying pathogenic mechanism of AD are currently being
tested in clinical trials. However, the clinically relevant implemen-
tation of any therapy depends on the reliability of the diagnosis.
Currently, the diagnosis of AD follows a logical sequence: family
history information, mental assessment, and the physical exami-
nation which, thus far, focuses on neurological signs (Burns and
FIGURE 4 | Outline of the methodology used to determine serum
DHEA levels and formation in response to FeSO4 treatment (A).
Variation of DHEA levels before and after Fe2+ oxidation of human sera from
AD and age-matched control patients (adapted from Rammouz et al., 2011).
Iliffe, 2009). An accurate, easy, and speciﬁc non-invasive biochem-
ical test that correlates with clinical ﬁndings is needed. Our data
show that a blood assay based on the existence of an alternative
pathway for DHEA biosynthesis in the brain can be successfully
used as an early diagnostic tool forAD(Rammouz et al., 2011). The
results obtained demonstrate that the DHEA biosynthesis process
tightly correlates with cognitive deﬁcits of AD patients and could
allow one to discriminate MCI from AD. Such an assay could be
used to diagnose AD at a very early stage and to monitor the effect
of therapeutic modalities on disease evolution.
CONCLUSION
We initially reported a cell-speciﬁc alternative pathway for DHEA
synthesis in the human brain. These results suggested a model for
neurosteroid biosynthesis in the CNS. In the case of an oxida-
tive environment and increase in ROS due to ischemia, trauma,
or neurodegeneration, glia may also act as reservoirs of DHEA
by using the alternative pathway to produce this steroid. Thus,
DHEA synthesis via the alternative pathway may be a mechanism
by which the brain can protect sensitive areas against oxidative
stress or limit the spread of damage. If the cholesterol–cholesterol
peroxide-DHEA pathway does exist in the brain, or even in the
steroid-producing endocrine glands, then it is undoubtedly asso-
ciated with its own regulatory system (trophic factors, etc.) and
represents a new aspect of steroidogenesis.
If neither enzyme is speciﬁc, the hydroperoxide formed by
autoxidation and a non-speciﬁc enzyme catalyze the formation
of PREG from the autoxidized product, the physiological effects
due to the portion of ketosteroids formed through this spuri-
ous, non-speciﬁc mechanism might be inconsequential. Indeed,
a recent study pinpointed that the autoxidation of cholesterol
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constitutes a potential source of both the lipoidal and the sulfated
forms of the DHEA and PREG (Liere et al., 2009). Conversely,
considerable amounts of PREG and DHEA were released from
unknown precursor(s) present in the lipoidal fraction, distinct
from fatty acid ester conjugates. In fact, chromatographic andmass
spectrometric studies of the nature of the precursor(s) showed
that the autoxidation of brain cholesterol is responsible for the
release of PREG and DHEA from the lipoidal fraction (Liere et al.,
2009). However, in our recent report (Rammouz et al., 2011), we
observed that cholesterol levels do not change during the oxida-
tion process mediated by Fe2+. These results obtained in human
cells support the data on the ability of astrocytes and oligoden-
drocytes to synthesize DHEA. In conclusion, all different brain
model systems, including rat glioma cell lines, primary cultures
of human and rat oligodendrocytes and astrocytes, microsomes
from rat brain, rat brain organic extracts (Prasad et al., 1994;
Cascio et al., 1998, 2000; Brown et al., 2000, 2003; Liu et al.,
2009), and bovine brain microsomes (data not shown), demon-
strate the presence of a Fe2+-dependent, CYP17A1-independent
process of DHEA formation. Our recent data suggest that a still
unidentiﬁed precursor of DHEA in the oxidative pathway is absent
from the serum of AD patients and lead us to apply this spe-
ciﬁc trait in the diagnosis of the disease (Rammouz et al., 2011).
A blood test based on in vitro oxidative stress-mediated DHEA
increases may be a valuable diagnostic tool for identifying AD
at an early stage, monitoring AD progression, differentially diag-
nosing AD from MCI, and evaluating the efﬁcacy of various AD
treatments.
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